NasdaqGS - Nasdaq Real Time Price USD

Black Diamond Therapeutics, Inc. (BDTX)

Compare
2.5600 +0.0600 (+2.40%)
At close: December 13 at 4:00:02 PM EST
2.5500 -0.01 (-0.39%)
After hours: December 13 at 7:31:30 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for BDTX

Recent News: BDTX

View More
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks

US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks
Simply Wall St. 2 days ago

Black Diamond: Q3 Earnings Snapshot
Associated Press Finance last month
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks

Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
Simply Wall St. last month
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire last month
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire last month
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
GlobeNewswire 2 months ago
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug

Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Benzinga 2 months ago
Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations
GlobeNewswire 2 months ago
Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
GlobeNewswire 2 months ago
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
GlobeNewswire 2 months ago
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors
GlobeNewswire 4 months ago
View More

Related Tickers

VRDN Viridian Therapeutics, Inc.
17.85
-0.78%
 
STOK Stoke Therapeutics, Inc.
12.06
-2.11%
 
ALEC Alector, Inc.
1.9700
-3.43%
 
AKRO Akero Therapeutics, Inc.
28.89
-0.48%
 
NKTX Nkarta, Inc.
2.3400
+2.18%
 
SLDB Solid Biosciences Inc.
4.9100
+4.91%
 
DTIL Precision BioSciences, Inc.
5.44
-11.11%
 
ITOS iTeos Therapeutics, Inc.
7.68
-3.34%
 
GOSS Gossamer Bio, Inc.
0.9300
+2.20%
 
CGEM Cullinan Therapeutics, Inc.
11.75
-3.69%